ClinicalTrialsFinder

Iparomlimab and Tuvonralimab Clinical Trials in Guangzhou

1 recruitingGuangzhou, China

Showing 1–1 of 1 trials

Recruiting
Phase 2

Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC

Neoadjuvant TherapyClear Cell Renal Cell CarcinomaIparomlimab and Tuvonralimab
Sun Yat-sen University25 enrolled1 locationNCT07389629